ArticleFrontiers in oncology2021
FAPI-04 PET/CT Using [
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 57 citations in OpenAlex.
- [Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Fibroblast activation protein inhibitor (FAPI) PET imaging in pulmonary fibrosis: pathophysiology, clinical utility, and emerging theranostic applications.Respiratory research · 2026Review
- Peptide Drugs in Gastrointestinal Tumors: Integrating Targeting, Delivery, and Therapeutic Actions for Synergistic Strategies.Biomolecules · 2026Review
- [RMD open · 2026Article
- Prognostic Significance of Pretreatment [¹⁸F]ALF-NOTA-FAPI-04 PET/CT in Patients With Recurrent Gastric Cancer Undergoing Combined PD-1 Inhibitor and Chemotherapy.Korean journal of radiology · 2026Article
- Radiopharmaceuticals in Renal Imaging: A Comprehensive Review of Current Applications and Future Prospects.ACS omega · 2026Review
- Development and evaluation of a peptide-based radiotracer for targeting TIM-3 in preclinical models.Frontiers in immunology · 2026Article
- Nanomedicine Targeting Cancer-Associated Fibroblasts in Prostate Cancer: From Biological Mechanisms to Integrated Theranostic Strategies.International journal of nanomedicine · 2026Review
- Designing novel linagliptin analogs through combined generative artificial intelligence, molecular docking, molecular dynamics simulation, and binding energy estimation for targeting fibroblast activation protein.Frontiers in chemistry · 2026Article
- Head-to-head comparison of [Frontiers in medicine · 2026Article
- Evaluating the diagnostic performance of [European radiology · 2025Article
- Clinical significance of diffuse [EJNMMI research · 2025Article
- Comparison of Al[Frontiers in oncology · 2025Article
- Non-invasive assessment of IgA nephropathy severity with [Clinical kidney journal · 2024Article
- Article
- Targeting CXCR4/CXCL12 axis via [European journal of nuclear medicine and molecular imaging · 2024Article
- Automated Radiosynthesis of [Pharmaceuticals (Basel, Switzerland) · 2024Article
- [Clinical kidney journal · 2024Article
- Article
- Impact of fat intake on [Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.